search
Back to results

Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser

Primary Purpose

Melanosis

Status
Terminated
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
pulsed dye laser treatment
Kligman's Trio
Sponsored by
Centre Hospitalier Universitaire de Nice
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Melanosis

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Pregnant women or breastfeeding.
  • Skin type 5 or 6.

Exclusion Criteria:

  • Known allergy to the compounds of the Kligman preparation.
  • Refusal to put very high protection sunscreen during the study.
  • Concomitant use of topical products that might have an effect on melasma (topical steroids, retinoids, etc…)

Sites / Locations

  • CHU de Nice - 4 avenue Reine Victoria - Hôpital de Cimiez

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Arm A

Arm B

Arm Description

All patients will be treated by stabilized Kligman's trio with daily application during 4 months. After one month, the left side of the face will be treated with pulsed dye laser at the rate of 3 sessions (one every weeks). Applications of cream will be stopped on both side of the face for the 3 days following each laser session. Final visit will be scheduled 1 month after the end of applications of stabilized Kligman's trio. All the patients will used a sunscreen indication 50 + for the duration of the entire study. The patient is her own witness. They compare the hemiface treated without laser and the hemiface treated with the laser.

All patients will be treated by stabilized Kligman's trio at the rate of application in the evening during 4 months. After one month, the side of the right face will be treated by pulsed dye laser at the rase of 3 sessions spaced out by 3 weeks each. Applications will be stopped in the 3 days which will follow every session by laser with blown colouring agent. The patients will be seen again 1 month after the stopping of applications of stabilized Kligman's trio All patients will be used a sunscreen indication 50 + for the duration of study. The patient is her own witness. They compare the cheek treated without laser and the cheek treated with the laser.

Outcomes

Primary Outcome Measures

MASI score, standardized photos in direct, crossed polarized and UV light, relating to the security: 0 yes 1 N0

Secondary Outcome Measures

Clinical evaluation of potential side-effects (including post inflammatory pigmentation)

Full Information

First Posted
March 16, 2009
Last Updated
March 23, 2012
Sponsor
Centre Hospitalier Universitaire de Nice
search

1. Study Identification

Unique Protocol Identification Number
NCT00863278
Brief Title
Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser
Official Title
Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser; a Comparative Prospective Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2009
Overall Recruitment Status
Terminated
Study Start Date
March 2009 (undefined)
Primary Completion Date
March 2010 (Actual)
Study Completion Date
December 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Nice

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Melasma is an acquired disorder of pigmentation that leads to irregular pigmented patches on the face. Treatment is difficult and to date the best treatment option is the combination of hydroquinone, retinoic acid and steroids combined in topical daily application (called Kligman's trio). Q-switched pigmentary lasers are usually ineffective and can induce post inflammatory hyperpigmentation (PIH). Intense pulsed light can sometimes improve melasma but also induce PIH which limit their use. Recently, pulsed dye laser were demonstrated to be effective in treating some pigmentary defects. Associating blanching cream with hydroquinone to prevent PIH after laser or intense pulsed light has been already reported with success. The objective of the study is to compare in a prospective intra individual comparative trial the association of pulsed dye laser plus stabilized Kligman's trio to Kligman's trio alone. The secondary objective was to study the frequency and the intensity of the potential side effects including PIH.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Melanosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm A
Arm Type
Active Comparator
Arm Description
All patients will be treated by stabilized Kligman's trio with daily application during 4 months. After one month, the left side of the face will be treated with pulsed dye laser at the rate of 3 sessions (one every weeks). Applications of cream will be stopped on both side of the face for the 3 days following each laser session. Final visit will be scheduled 1 month after the end of applications of stabilized Kligman's trio. All the patients will used a sunscreen indication 50 + for the duration of the entire study. The patient is her own witness. They compare the hemiface treated without laser and the hemiface treated with the laser.
Arm Title
Arm B
Arm Type
Active Comparator
Arm Description
All patients will be treated by stabilized Kligman's trio at the rate of application in the evening during 4 months. After one month, the side of the right face will be treated by pulsed dye laser at the rase of 3 sessions spaced out by 3 weeks each. Applications will be stopped in the 3 days which will follow every session by laser with blown colouring agent. The patients will be seen again 1 month after the stopping of applications of stabilized Kligman's trio All patients will be used a sunscreen indication 50 + for the duration of study. The patient is her own witness. They compare the cheek treated without laser and the cheek treated with the laser.
Intervention Type
Procedure
Intervention Name(s)
pulsed dye laser treatment
Intervention Description
On one side of the face according to Arm placement.
Intervention Type
Drug
Intervention Name(s)
Kligman's Trio
Intervention Description
The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
Primary Outcome Measure Information:
Title
MASI score, standardized photos in direct, crossed polarized and UV light, relating to the security: 0 yes 1 N0
Time Frame
visit of screening (V0), 15 days after V0 during the follow visit 1(V1), 3 weeks after V1 during the following visit 2(V2), 3 weeks after V2 during the following visit 3(V3), 10 weeks after V3 during the following visit 4
Secondary Outcome Measure Information:
Title
Clinical evaluation of potential side-effects (including post inflammatory pigmentation)
Time Frame
visit of screening (V0), 15 days after V0 during the follow visit 1(V1), 3 weeks after V1 during the following visit 2(V2), 3 weeks after V2 during the following visit 3(V3), 10 weeks after V3 during the following visit 4

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pregnant women or breastfeeding. Skin type 5 or 6. Exclusion Criteria: Known allergy to the compounds of the Kligman preparation. Refusal to put very high protection sunscreen during the study. Concomitant use of topical products that might have an effect on melasma (topical steroids, retinoids, etc…)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
PASSERON Ph Thierry, MD
Organizational Affiliation
CHU de Nice - Service de Dermatologie - Hôpital de l'Archet - 151 Route de saint-antoine de ginestière 06200 Nice
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Nice - 4 avenue Reine Victoria - Hôpital de Cimiez
City
Nice
State/Province
Alpes-Maritimes
ZIP/Postal Code
06001
Country
France

12. IPD Sharing Statement

Learn more about this trial

Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser

We'll reach out to this number within 24 hrs